{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:27:56Z","timestamp":1770233276373,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["294229"],"award-info":[{"award-number":["294229"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["294227"],"award-info":[{"award-number":["294227"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["307057"],"award-info":[{"award-number":["307057"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["311939"],"award-info":[{"award-number":["311939"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bmcl.2018.07.030","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T23:48:07Z","timestamp":1532044087000},"page":"2856-2860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug"],"prefix":"10.1016","volume":"28","author":[{"given":"Nikki A.","family":"Thiele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussi","family":"K\u00e4rkk\u00e4inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth B.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarkko","family":"Rautio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiina M.","family":"Huttunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2018.07.030_b0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bmb\/ldn013","article-title":"A review of Parkinson's disease","volume":"86","author":"Davie","year":"2008","journal-title":"Br Med Bull"},{"key":"10.1016\/j.bmcl.2018.07.030_b0010","doi-asserted-by":"crossref","first-page":"17,013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.bmcl.2018.07.030_b0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1478-811X-11-34","article-title":"Complexity of dopamine metabolism","volume":"11","author":"Meiser","year":"2013","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.bmcl.2018.07.030_b0020","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson's disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.bmcl.2018.07.030_b0025","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/466S6a","article-title":"Levodopa: the story so far","volume":"466","author":"Abbott","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2018.07.030_b0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0006-8993(00)02758-X","article-title":"The 4F2hc\/LAT1 complex transports l-DOPA across the blood-brain barrier","volume":"879","author":"Kageyama","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.bmcl.2018.07.030_b0035","doi-asserted-by":"crossref","first-page":"S580","DOI":"10.1002\/mds.22037","article-title":"Pharmacokinetics and pharmacodynamics of levodopa","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.bmcl.2018.07.030_b0040","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jcph.514","volume":"55","author":"Hsu","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2018.07.030_b0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2018.07.030_b0050","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s11095-012-0966-3","article-title":"Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine","volume":"30","author":"Peura","year":"2013","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmcl.2018.07.030_b0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2017.06.023","article-title":"l-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs","volume":"261","author":"Puris","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.bmcl.2018.07.030_b0060","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1021\/mp2001878","article-title":"Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery","volume":"8","author":"Peura","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmcl.2018.07.030_b0065","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s11064-016-1996-8","article-title":"Amino acid promoieties alter valproic acid pharmacokinetics and enable extended brain exposure","volume":"41","author":"Gynther","year":"2016","journal-title":"Neurochem Res"},{"key":"10.1016\/j.bmcl.2018.07.030_b0070","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acs.molpharmaceut.6b00217","article-title":"Systemic and brain pharmacokinetics of perforin inhibitor prodrugs","volume":"13","author":"Gynther","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmcl.2018.07.030_b0080","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1039\/c39720000500","article-title":"Isocyanate intermediates in Elcb mechanism of carbamate hydrolysis","volume":"9","author":"Hegarty","year":"1972","journal-title":"J Chem Soc Chem Commun"},{"key":"10.1016\/j.bmcl.2018.07.030_b0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0378-5173(92)90017-V","article-title":"Phenyl carbamates of amino acids as prodrugs forms for protecting phenols against first-pass metabolism","volume":"81","author":"Hansen","year":"1992","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bmcl.2018.07.030_b0090","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1021\/jm501371s","article-title":"Organic carbamates in drug design and medicinal chemistry","volume":"58","author":"Ghosh","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.07.030_b0095","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1476-5381.1976.tb10377.x","article-title":"The ionization of phenolic amines, including apomorphine, dopamine and catecholamines and an assessment of zwitterion constants","volume":"57","author":"Armstrong","year":"1976","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2018.07.030_b0100","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1476-5381.1954.tb00866.x","article-title":"The importance of ionization in the activity of sympathomimetic amines","volume":"9","author":"Lewis","year":"1954","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1016\/j.bmcl.2018.07.030_b0105","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1021\/acs.jmedchem.6b00190","article-title":"A selective and slowly reversible inhibitor of l-Type amino acid transporter 1 (LAT1) potentiates antiproliferative drug efficacy in cancer cells","volume":"59","author":"Huttunen","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2018.07.030_b0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijpharm.2015.12.034","article-title":"l-type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors","volume":"498","author":"Huttunen","year":"2016","journal-title":"Int J Pharm"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18306085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18306085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:24:28Z","timestamp":1760772268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X18306085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0960894X18306085"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.07.030","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}